# Safety and Efficacy of Deferasirox in Patients With Transfusion Dependent Iron Overload - a Non-comparative Extension Study

> **NCT01033747** · PHASE2,PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 70 (actual)

## Conditions studied

- Liver Iron Overload

## Interventions

- **DRUG:** Deferasirox
- **DRUG:** Deferasirox

## Key facts

- **NCT ID:** NCT01033747
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-02
- **Primary completion:** 2008-01
- **Final completion:** 2008-01
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2011-08-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01033747

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01033747, "Safety and Efficacy of Deferasirox in Patients With Transfusion Dependent Iron Overload - a Non-comparative Extension Study". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01033747. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*